NO20056073L - Sammensetninger og fremgangsmater til behandling av alvorlig akutt respitatorisk syndrom (SARS) - Google Patents

Sammensetninger og fremgangsmater til behandling av alvorlig akutt respitatorisk syndrom (SARS)

Info

Publication number
NO20056073L
NO20056073L NO20056073A NO20056073A NO20056073L NO 20056073 L NO20056073 L NO 20056073L NO 20056073 A NO20056073 A NO 20056073A NO 20056073 A NO20056073 A NO 20056073A NO 20056073 L NO20056073 L NO 20056073L
Authority
NO
Norway
Prior art keywords
sars
methods
compositions
acute respiratory
respiratory syndrome
Prior art date
Application number
NO20056073A
Other languages
English (en)
Norwegian (no)
Inventor
George R Siber
Original Assignee
Wyeth Holdings Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Holdings Co filed Critical Wyeth Holdings Co
Publication of NO20056073L publication Critical patent/NO20056073L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Communicable Diseases (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NO20056073A 2003-05-20 2005-12-20 Sammensetninger og fremgangsmater til behandling av alvorlig akutt respitatorisk syndrom (SARS) NO20056073L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/441,059 US7892563B2 (en) 2003-05-20 2003-05-20 Methods for treatment of severe acute respiratory syndrome (SARS)
PCT/US2004/015864 WO2005018535A2 (en) 2003-05-20 2004-05-20 Compositions and methods for treatment of severe acute respiratory syndrome (sars)

Publications (1)

Publication Number Publication Date
NO20056073L true NO20056073L (no) 2005-12-20

Family

ID=33449934

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20056073A NO20056073L (no) 2003-05-20 2005-12-20 Sammensetninger og fremgangsmater til behandling av alvorlig akutt respitatorisk syndrom (SARS)

Country Status (14)

Country Link
US (2) US7892563B2 (pt)
EP (1) EP1624850A4 (pt)
JP (1) JP2007525465A (pt)
KR (1) KR20060023968A (pt)
CN (1) CN1976720A (pt)
AU (1) AU2004266111B8 (pt)
BR (1) BRPI0410467A (pt)
CA (1) CA2526431A1 (pt)
IL (1) IL171972A0 (pt)
MX (1) MXPA05012497A (pt)
NO (1) NO20056073L (pt)
NZ (1) NZ543655A (pt)
RU (1) RU2411042C2 (pt)
WO (1) WO2005018535A2 (pt)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9028822B2 (en) 2002-06-28 2015-05-12 Domantis Limited Antagonists against TNFR1 and methods of use therefor
US20080008713A1 (en) * 2002-06-28 2008-01-10 Domantis Limited Single domain antibodies against tnfr1 and methods of use therefor
US9296795B2 (en) 2003-03-07 2016-03-29 Wyeth Holdings, Llc. Polysaccharide-staphylococcal surface adhesin carrier protein conjugates for immunization against nosocomial infections
JP4845091B2 (ja) * 2005-08-09 2011-12-28 学校法人日本大学 コロナウィルスの遺伝子を切断するリボザイム
US20100247525A1 (en) * 2006-05-08 2010-09-30 University Of Virginia Patent Foundation Compositions and methods for treating anthrax lethality
CA2657581A1 (en) * 2006-07-11 2008-01-17 Roy C. Levitt Rhinosinusitis prevention and therapy with proinflammatory cytokine inhibitors
US8722615B2 (en) * 2009-12-02 2014-05-13 Acceleron Pharma, Inc. Compositions and methods for increasing serum half-life
AU2012256683B2 (en) 2011-05-19 2017-02-02 Mochida Pharmaceutical Co., Ltd. Diagnosis of respiratory tract infectious diseases using urine specimens
US8883982B2 (en) 2011-06-08 2014-11-11 Acceleron Pharma, Inc. Compositions and methods for increasing serum half-life
CN111228480A (zh) * 2020-02-24 2020-06-05 浙江正熙生物医药有限公司 抗人TNF-α抗体在制备用于治疗病毒感染的药物中的应用
WO2021183195A1 (en) 2020-03-09 2021-09-16 1.Abcellera Biologics Inc. Anti-coronavirus antibodies and methods of use
CN115996741A (zh) * 2020-03-11 2023-04-21 百欧林纳克斯有限公司 用于治疗急性呼吸窘迫综合征及病毒感染的cxcr4抑制剂
WO2021186438A1 (en) * 2020-03-16 2021-09-23 Bar-Ilan University Molecules that target proteins of coronaviruses and uses thereof as anti-viral "cocktail"
CN113425722B (zh) * 2020-03-23 2025-06-24 上海市浦东新区公利医院(第二军医大学附属公利医院) 苦味受体激动剂及其在预防和治疗SARS-CoV-2相关传染病中的应用
CR20220552A (es) 2020-04-02 2023-01-17 Regeneron Pharma Anticuerpos contra glicoproteína de espícula anti-sars-cov-2 y fragmentos de unión al antígeno
EP4061349A4 (en) * 2020-04-03 2023-09-06 Veru Inc. CORONAVIRUS TREATMENT METHODS
JP2023521358A (ja) * 2020-04-08 2023-05-24 ノストラム ファーマシューティカルス，エルエルシー ウイルス性呼吸器感染症を治療するためのインターフェロンを使用する組成物及び方法
US20230218710A1 (en) * 2020-04-15 2023-07-13 Cohbar, Inc. Method of treating coronavirus infections
IL274327A (en) * 2020-04-28 2021-10-31 Zaltzman Pinchas Antiviral preparations
EP3906922A1 (en) * 2020-05-07 2021-11-10 4Living Biotech New compositions and methods of treating covid-19 disease
WO2021226437A1 (en) * 2020-05-07 2021-11-11 Bio-Rad Laboratories, Inc. Sars-cov-2 immunoassay and materials therefor
MX2022014083A (es) * 2020-05-15 2023-02-22 Altered Labs Llc Kit de tratamiento de suplemento de refuerzo inmunologico y metodos de uso.
US11740240B2 (en) * 2020-07-20 2023-08-29 Bio-Rad Laboratories, Inc. Immunoassay for SARS-CoV-2 neutralizing antibodies and materials therefor
EP3957364A1 (en) * 2020-08-20 2022-02-23 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. A binding molecule specifically binding to human cd4 for use in the treatment of pulmonary diseases
US20220273641A1 (en) * 2020-10-07 2022-09-01 Vera Mikhailov Method for treating coronavirus infections including SARS-CoV-2
WO2022264097A1 (en) * 2021-06-17 2022-12-22 Lupin Limited Pharmaceutical composition of anti-tumour necrosis factor (anti-tnf) agent for management of infectious diseases caused by coronaviruses
CA3225575A1 (en) 2021-07-14 2023-01-19 Regeneron Pharmaceuticals, Inc. Anti-sars-cov-2-spike glycoprotein antibodies and antigen-binding fragments

Family Cites Families (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US4699880A (en) 1984-09-25 1987-10-13 Immunomedics, Inc. Method of producing monoclonal anti-idiotype antibody
US4720489A (en) 1984-10-15 1988-01-19 Douglas Shander Hair growth modification with ornithine decarboxylase inhibitors
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
EP0613006A1 (en) 1985-08-16 1994-08-31 The Rockefeller University Antibodies to cachectin and immunoassays
US4870163A (en) 1985-08-29 1989-09-26 New York Blood Center, Inc. Preparation of pure human tumor necrosis factor and hybridomas producing monoclonal antibodies to human tumor necrosis factor
US5116742A (en) 1986-12-03 1992-05-26 University Patents, Inc. RNA ribozyme restriction endoribonucleases and methods
US4987071A (en) 1986-12-03 1991-01-22 University Patents, Inc. RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods
US5096906A (en) 1986-12-31 1992-03-17 University Of Virginia Alumni Patents Foundation Method of inhibiting the activity of leukocyte derived cytokines
US5196430A (en) 1986-12-31 1993-03-23 Hoechst-Roussel Pharmaceuticals Inc. Method of inhibiting the activity of leukocyte derived cytokines
DE3888224T2 (de) 1987-04-24 1994-07-21 Teijin Ltd Bestimmung vom Tumornekrosefaktor; monoklonaler Antikörper und Zusammensetzung.
US4904582A (en) 1987-06-11 1990-02-27 Synthetic Genetics Novel amphiphilic nucleic acid conjugates
IL83878A (en) 1987-09-13 1995-07-31 Yeda Res & Dev Soluble protein corresponding to tnf inhibitory protein its preparation and pharmaceutical compositions containing it
DE3817955A1 (de) 1988-05-27 1989-11-30 Hoechst Ag Tnf-inhibitor enthaltendes arzneimittel
IL94039A (en) 1989-08-06 2006-09-05 Yeda Res & Dev Antibodies to tbp - 1 and their use
ATE119942T1 (de) 1989-05-18 1995-04-15 Yeda Res & Dev Tumor-nekrosefaktor-bindungsprotein ii, seine reinigung und spezifische antikörper.
GB9413975D0 (en) 1994-07-11 1994-08-31 Fujisawa Pharmaceutical Co New heterobicyclic derivatives
JP3443119B2 (ja) 1989-08-07 2003-09-02 ペプテック リミテッド 腫瘍壊死因子結合リガンド
US5395760A (en) 1989-09-05 1995-03-07 Immunex Corporation DNA encoding tumor necrosis factor-α and -β receptors
US5605690A (en) 1989-09-05 1997-02-25 Immunex Corporation Methods of lowering active TNF-α levels in mammals using tumor necrosis factor receptor
AU642938B2 (en) 1989-12-13 1993-11-04 Yeda Research And Development Co. Ltd. Expression of the recombinant tumor necrosis factor binding protein 1 (TBP-1)
DE4027616A1 (de) 1990-08-31 1992-03-05 Boehringer Mannheim Gmbh Verfahren zur bestimmung von polymerase-aktivitaet
GB9022648D0 (en) 1990-10-18 1990-11-28 Charing Cross Sunley Research Polypeptide and its use
GB9109645D0 (en) 1991-05-03 1991-06-26 Celltech Ltd Recombinant antibodies
GB9028123D0 (en) 1990-12-28 1991-02-13 Erba Carlo Spa Monoclonal antibodies against human tumor necrosis factor alpha
CA2100329C (en) 1991-01-18 2009-09-29 David F. Carmichael Methods for treating tumor necrosis factor mediated diseases
US5656272A (en) 1991-03-18 1997-08-12 New York University Medical Center Methods of treating TNF-α-mediated Crohn's disease using chimeric anti-TNF antibodies
US6277969B1 (en) 1991-03-18 2001-08-21 New York University Anti-TNF antibodies and peptides of human tumor necrosis factor
DE69232586T2 (de) 1991-07-05 2002-11-28 Peptech Ltd., North Ryde Giftigkeit von tnf und lps ausschaltende peptide
IL99120A0 (en) 1991-08-07 1992-07-15 Yeda Res & Dev Multimers of the soluble forms of tnf receptors,their preparation and pharmaceutical compositions containing them
US5547979A (en) 1992-03-30 1996-08-20 Smithkline Beecham TNF inhibition
GB9223904D0 (en) 1992-11-13 1993-01-06 British Bio Technology Inhibition of cytokine production
US5594106A (en) 1993-08-23 1997-01-14 Immunex Corporation Inhibitors of TNF-α secretion
GB9320660D0 (en) 1993-10-07 1993-11-24 British Bio Technology Inhibition of cytokine production
US5508300A (en) 1994-01-14 1996-04-16 Pfizer Inc. Dihydro pyrazolopyrroles, compositions and use
PT822186E (pt) 1994-01-20 2000-08-31 British Biotech Pharm L-tert-leucina-2-piridilamida
GB9412672D0 (en) 1994-06-23 1994-08-10 Celltech Ltd Chemical compounds
EP0766564A4 (en) 1994-06-24 1998-09-23 Immunex Corp SLOW RELEASE POLYPEPTIDES COMPOSITIONS AND METHODS FOR TREATING INFLAMMATORY BOWEL CONDITIONS
GB2291422A (en) 1994-07-18 1996-01-24 Fujisawa Pharmaceutical Co 4-phenyl-pyrido[2,3-b]pyrazin-4-ones
US5563143A (en) 1994-09-21 1996-10-08 Pfizer Inc. Catechol diether compounds as inhibitors of TNF release
US6107273A (en) 1995-01-24 2000-08-22 Thomas Jefferson University Tumor necrosis factor inhibitors
IL112834A (en) 1995-03-01 2000-12-06 Yeda Res & Dev Pharmaceutical compositions for controlled release of soluble receptors
US5863949A (en) 1995-03-08 1999-01-26 Pfizer Inc Arylsulfonylamino hydroxamic acid derivatives
DK0821671T3 (da) 1995-04-20 2001-04-23 Pfizer Arylsulfonylhydroxamsyrederivater som MMP- og TNF-inhibitorer
US5824519A (en) 1995-11-08 1998-10-20 Medical University Of South Carolina Tissue-specific and target RNA-specific ribozymes
GB9607120D0 (en) 1996-04-04 1996-06-12 Chiroscience Ltd Compounds
WO1997044322A1 (en) 1996-05-20 1997-11-27 Darwin Discovery Limited Quinoline sulfonamides as tnf inhibitors and as pde-iv inhibitors
AU4988697A (en) 1996-10-24 1998-05-15 Vion Pharmaceuticals, Inc. Monophosphate prodrugs of beta-l-fd4c and beta-l-fddc as potent antiviral agents
US5833994A (en) 1997-01-08 1998-11-10 Paracelsian, Inc. Use of the AH receptor and AH receptor ligands to treat or prevent cytopathicity of viral infection
US6140368A (en) 1997-05-05 2000-10-31 The Regents Of The University Of California Naphthols useful in antiviral methods
US6071743A (en) 1997-06-02 2000-06-06 Subsidiary No. 3, Inc. Compositions and methods for inhibiting human immunodeficiency virus infection by down-regulating human cellular genes
US5883131A (en) 1997-07-09 1999-03-16 Pfizer Inc. Cyclic sulfone derivatives
AU9013998A (en) 1997-07-21 1999-02-10 Zymogenetics Inc. Tumor necrosis factor receptor ztnfr-5
WO1999015524A1 (en) 1997-09-23 1999-04-01 Fujisawa Pharmaceutical Co., Ltd. Thiazole derivatives
US6020339A (en) 1997-10-03 2000-02-01 Merck & Co., Inc. Aryl furan derivatives as PDE IV inhibitors
DE19813802A1 (de) 1998-03-27 1999-11-11 Retro Tech Gmbh Anti-virale Wirkung von Propolis durch Inhibition viraler Nukleinsäure Polymerasen
US6251868B1 (en) 1998-04-30 2001-06-26 Teijin Limited Method for treating a human immunodeficiency virus infection
BR9911457A (pt) 1998-06-24 2001-12-11 Univ Emory Uso de 3'-azida-2', 3'-dideoxiuridina em combinaçãocom drogas anti-hiv adicionais para a manufaturade um medicamento para o tratamento de hiv
AU5297299A (en) 1998-08-17 2000-03-06 Patrick T. Prendergast Cytokine and cytokine receptor, agonist, antagonist and/or antibody combination for therapeutic use
US6080580A (en) 1998-10-05 2000-06-27 Isis Pharmaceuticals Inc. Antisense oligonucleotide modulation of tumor necrosis factor-α (TNF-α) expression
US6114517A (en) 1998-12-10 2000-09-05 Isis Pharmaceuticals Inc. Methods of modulating tumor necrosis factor α-induced expression of cell adhesion molecules
US6419934B1 (en) * 1999-02-24 2002-07-16 Edward L. Tobinick TNF modulators for treating neurological disorders associated with viral infection
SG101418A1 (en) * 1999-03-30 2004-01-30 Showa Denko Kk Production process for magnetic recording medium
US20010021380A1 (en) 1999-04-19 2001-09-13 Pluenneke John D. Soluble tumor necrosis factor receptor treatment of medical disorders
US6632667B1 (en) * 1999-10-28 2003-10-14 Isis Pharmaceuticals, Inc. Modulation of L-selectin shedding via inhibition of tumor necrosis factor-α converting enzyme (TACE)
US7056695B2 (en) * 2000-03-02 2006-06-06 Xencor TNF-α variants
CA2385745C (en) * 2001-06-08 2015-02-17 Abbott Laboratories (Bermuda) Ltd. Methods of administering anti-tnf.alpha. antibodies

Also Published As

Publication number Publication date
RU2005139730A (ru) 2006-05-10
CA2526431A1 (en) 2005-03-03
CN1976720A (zh) 2007-06-06
IL171972A0 (en) 2006-04-10
BRPI0410467A (pt) 2006-05-30
US7892563B2 (en) 2011-02-22
NZ543655A (en) 2009-07-31
US20060263847A1 (en) 2006-11-23
JP2007525465A (ja) 2007-09-06
AU2004266111A1 (en) 2005-03-03
US7722886B2 (en) 2010-05-25
WO2005018535A3 (en) 2006-12-21
RU2411042C2 (ru) 2011-02-10
AU2004266111B2 (en) 2010-08-26
EP1624850A4 (en) 2007-10-31
EP1624850A2 (en) 2006-02-15
WO2005018535A2 (en) 2005-03-03
MXPA05012497A (es) 2006-07-03
AU2004266111B8 (en) 2010-12-23
KR20060023968A (ko) 2006-03-15
US20040235047A1 (en) 2004-11-25

Similar Documents

Publication Publication Date Title
NO20056073L (no) Sammensetninger og fremgangsmater til behandling av alvorlig akutt respitatorisk syndrom (SARS)
ATE517896T1 (de) P38-kinase-inhibitoren
MY169308A (en) Treatment of tnf? related disorders
IS2130B (is) Glútamín-þíasólidíð og -pýrrólidíð og notkun þeirra sem dípeptidýlpeptíðasa IV hindrar
GB0402143D0 (en) Novel compounds
DE60327999D1 (de) Azolylaminoazine als inhibitoren von proteinkinasen
DK1651161T3 (da) Farmaceutiske præparater og fremgangsmåder til at fremme sårheling
EA200870019A1 (ru) Лактамовые соединения и способы их применения
NO20052595L (no) Sammensetninger anvendelige som inhibitorer av ROCK- og andre proteinkinaser.
CY1105080T1 (el) Ενωσεις θειενοπυρρολυλιου και φουρανοπυρρολυλιου και η χρηση τους ως συνδετες η4 υποδοχεα ισταμινης
DK1809280T3 (da) Mitotiske kinesininhibitorer og fremgangsmåder til anvendelse deraf
NO20034094L (no) Sammensetninger som omfatter et antidiar±middel og et epotilon eller et epotilonderivat
WO2003024386A8 (en) Use of potent, selective and non toxic c-kit inhibitors for treating interstitial cystitis
NO20061291L (no) Ny formulering
GB0402138D0 (en) Novel compounds
ATE499098T1 (de) Verwendung von parp-1-hemmern
NO20062336L (no) Kombinasjoner av kaliumkanalapnere og natriumkanalinhibitorer eller aktive substanser som pavirker natriumkanaler for behandling av smertetilstander
NO20065079L (no) Materialer og metoder for behandling av koaguleringssykdommer
DK1441708T3 (da) Sammensætninger og fremgangsmåder til forögelse af föjelighed med terapier ved anvendelse af aldehyddehydrogenase-inhibitorer og behandling af alkoholisme
DK1567139T3 (da) Hidtil ukendt synergistisk kombination der omfatter roflumilast og formoterol
NO20080495L (no) PEG-IFN-alfa og ribavirin for HBV-behandling
ATE536874T1 (de) Dreifache monoamin-wiederaufnahmehemmer zur behandlung von chronischen schmerzen
ATE392212T1 (de) Verwendung eines proteasom-inhibitors zur behandlung fibrotischer erkrankungen
WO2006096769A3 (en) Use of alpha-glucosidase inhibitors to treat alphavirus infections
DK1455770T3 (da) Anvendelse af norepinephringenoptagelsesinhibitorer til behandling af tic lidelser

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application